PT3514172T - Imunorrecetores específicos de claudina-6 e epítopos de células t - Google Patents

Imunorrecetores específicos de claudina-6 e epítopos de células t

Info

Publication number: PT3514172T
Authority: PT; Portugal
Prior art keywords: epitioes; claudin; cell; immunoreceptors; specific immunoreceptors
Prior art date: 2014-04-01

Application number

PT191512383T

Other languages

English (en)

Original Assignee

Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh

Biontech Cell & Gene Therapies Gmbh

Ganymed Pharmaceuticals Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-04-01

Filing date

2015-03-30

Publication date

2020-04-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52745896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3514172(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-03-30 Application filed by Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh, Biontech Cell & Gene Therapies Gmbh, Ganymed Pharmaceuticals Gmbh filed Critical Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh

2020-04-21 Publication of PT3514172T publication Critical patent/PT3514172T/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Cell Biology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
General Physics & Mathematics (AREA)
Biotechnology (AREA)
Pathology (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Analytical Chemistry (AREA)
Tropical Medicine & Parasitology (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Hospice & Palliative Care (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)

PT191512383T 2014-04-01 2015-03-30 Imunorrecetores específicos de claudina-6 e epítopos de células t PT3514172T (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP2014000868		2014-04-01
EP2014072864		2014-10-24

Publications (1)

Publication Number	Publication Date
PT3514172T true PT3514172T (pt)	2020-04-21

Family

ID=52745896

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PT15712657T PT3126381T (pt)	2014-04-01	2015-03-30	Imunorrecetores e epítopos de células t específicos da claudina-6
PT201601416T PT3708579T (pt)	2014-04-01	2015-03-30	Imunorrecetores e epitopos de células t específicos para claudina-6
PT191512383T PT3514172T (pt)	2014-04-01	2015-03-30	Imunorrecetores específicos de claudina-6 e epítopos de células t

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PT15712657T PT3126381T (pt)	2014-04-01	2015-03-30	Imunorrecetores e epítopos de células t específicos da claudina-6
PT201601416T PT3708579T (pt)	2014-04-01	2015-03-30	Imunorrecetores e epitopos de células t específicos para claudina-6

Country Status (21)

Country	Link
US (3)	US10370423B2 (pt)
EP (3)	EP3126381B2 (pt)
JP (3)	JP6726656B2 (pt)
CN (3)	CN113150109A (pt)
AU (3)	AU2015239683B2 (pt)
BR (1)	BR112016022727A8 (pt)
CA (1)	CA2942459C (pt)
CY (1)	CY1121539T1 (pt)
DK (3)	DK3514172T3 (pt)
ES (3)	ES2982838T3 (pt)
FI (1)	FI3708579T3 (pt)
HR (2)	HRP20240926T1 (pt)
HU (3)	HUE044515T2 (pt)
LT (2)	LT3126381T (pt)
ME (1)	ME03407B (pt)
MX (1)	MX2016012713A (pt)
PL (3)	PL3514172T3 (pt)
PT (3)	PT3126381T (pt)
RS (2)	RS58627B2 (pt)
SI (3)	SI3514172T1 (pt)
WO (1)	WO2015150327A1 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2649389T3 (es) *	2009-11-11	2018-01-11	Ganymed Pharmaceuticals Gmbh	Anticuerpos específicos para claudina 6 (CLDN6)
EP2888283B1 (en)	2012-08-24	2018-09-19	The Regents of The University of California	Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
MX2016005763A (es)	2013-11-06	2016-08-19	Stemcentrx Inc	Anticuerpos anti-claudina novedosos y metodos de uso.
MA40921A (fr) *	2014-11-05	2017-09-12	Abbvie Stemcentrx Llc	Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
EP3808770A1 (en)	2014-11-14	2021-04-21	The U.S.A. as represented by the Secretary, Department of Health and Human Services	Human anti-thyroglobulin t cell receptors
CN106146666B (zh) *	2015-03-26	2019-09-06	科济生物医药（上海）有限公司	靶向cldn6的免疫效应细胞及其制备方法和应用
WO2016180468A1 (en)	2015-05-11	2016-11-17	Biontech Cell & Gene Therapies Gmbh	Claudin-18.2-specific immunoreceptors and t cell epitopes
WO2016180467A1 (en) *	2015-05-11	2016-11-17	Biontech Cell & Gene Therapies Gmbh	Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
MX2017014822A (es)	2015-05-18	2018-04-30	Tcr2 Therapeutics Inc	Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
IL293719B2 (en)	2015-05-21	2023-07-01	Harpoon Therapeutics Inc	Trispecific binding proteins and methods of use
GB201520550D0 (en)	2015-11-23	2016-01-06	Immunocore Ltd & Adaptimmune Ltd	Peptides
GB201520568D0 (en)	2015-11-23	2016-01-06	Immunocore Ltd	Peptides
GB201607534D0 (en)	2016-04-29	2016-06-15	Immunocore Ltd & Adaptimmune Ltd	Peptides
CN114028549A (zh)	2016-02-19	2022-02-11	伊玛提克斯生物技术有限公司	用于nhl和其他癌症免疫治疗的新型肽和肽组合物
GB201602918D0 (en)	2016-02-19	2016-04-06	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
JP2019527537A (ja) *	2016-06-07	2019-10-03	マックス−デルブリュック−セントルムフュールモレキュラーメディツィンインデアヘルムホルツ−ゲマインシャフト	キメラ抗原受容体と、ｂｃｍａに結合するｃａｒ−ｔ細胞
MX2018016330A (es)	2016-06-27	2020-02-17	Univ California	Combinaciones para tratamiento del cáncer.
JP7138630B2 (ja)	2016-07-14	2022-09-16	ゲンマブエー／エス	Ｃｄ４０およびｃｄ１３７に対する多重特異性抗体
MX2019003899A (es) *	2016-10-07	2019-08-14	Tcr2 Therapeutics Inc	Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
KR102375033B1 (ko) *	2017-03-15	2022-03-15	프레드 헛친슨 켄서 리서치 센터	고친화도 mage-a1-특이적 tcr 및 이의 용도
KR102333377B1 (ko) *	2017-03-27	2021-11-30	노일 이뮨 바이오테크 가부시키가이샤	키메라 항원 수용체
SG11202000198QA (en)	2017-08-04	2020-02-27	Genmab As	Binding agents binding to pd-l1 and cd137 and use thereof
BR112020005196A2 (pt) *	2017-09-18	2020-09-15	The Regents Of The University Of California	anticorpos claudin6 e métodos para tratar câncer
WO2019065964A1 (ja)	2017-09-29	2019-04-04	第一三共株式会社	抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
EP3877409A1 (en)	2018-11-06	2021-09-15	Genmab A/S	Antibody formulation
KR20210102231A (ko) *	2018-11-09	2021-08-19	프레드 헛친슨 켄서 리서치 센터	메소텔린에 특이적인 t 세포 수용체 및 면역요법에서의 그의 용도
KR20210100656A (ko) *	2018-12-05	2021-08-17	제넨테크, 인크.	암 면역요법을 위한 진단 방법 및 조성물
CU20210067A7 (es) *	2019-02-08	2022-03-07	Biontech Cell & Gene Therapies Gmbh	Molécula de receptor de antígeno quimérico con dominio de unión al antígeno cldn6
US20220155321A1 (en) *	2019-03-01	2022-05-19	Gritstone bio, Inc	Selection of t cell receptors
CN114174340A (zh)	2019-03-20	2022-03-11	加利福尼亚大学董事会	密封蛋白-6抗体和药物缀合物
WO2021129927A1 (en) *	2019-12-23	2021-07-01	Biontech Cell & Gene Therapies Gmbh	Treatment with immune effector cells engineered to express an antigen receptor
US20230087164A1 (en)	2020-02-04	2023-03-23	Genmab A/S	Antibodies for use in therapy
MX2023005386A (es)	2020-11-11	2023-05-23	BioNTech SE	Anticuerpos monoclonales dirigidos contra la proteina de muerte programada-1 y su uso en medicina.
US20240216427A1 (en) *	2020-12-30	2024-07-04	St. Jude Children's Research Hospital, Inc.	Chimeric antigen receptors targeting splice variants of the extracellular matrix proteins tenascin c (tnc) and procollagen 11a1 (col11a1)
EP4359435A1 (en)	2021-06-21	2024-05-01	Genmab A/S	Combination dosage regime of cd137 and pd-l1 binding agents
IL309831A (en)	2021-07-13	2024-02-01	BioNTech SE	Multispecific binding agents against CD40 and CD137 in combined cancer therapy
EP4395823A2 (en) *	2021-09-03	2024-07-10	NovaRock Biotherapeutics, Ltd.	Bispecific binding proteins that bind cd137 and a tumor associated antigen
CA3234647A1 (en)	2021-10-06	2023-04-13	Genmab A/S	Multispecific binding agents against pd-l1 and cd137 in combination therapy
KR20240082387A (ko)	2021-10-06	2024-06-10	젠맵 에이/에스	암을 치료하기 위한 항 pd-1 항체와 조합된 pd-l1 및 cd137에 대한 다중특이적 결합제
WO2023064899A1 (en) *	2021-10-14	2023-04-20	Health Research, Inc.	Compositions and methods for use of recombinant t cell receptors against claudin 6
WO2023218046A1 (en)	2022-05-12	2023-11-16	Genmab A/S	Binding agents capable of binding to cd27 in combination therapy
US11932693B2 (en)	2022-05-12	2024-03-19	BioNTech SE	Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
TW202409090A (zh)	2022-05-12	2024-03-01	丹麥商珍美寶股份有限公司	在組合療法中能夠結合到ｃｄ２７之結合劑
CN115232207B (zh) *	2022-05-19	2023-06-13	河南大学	抗体-溶菌素（SM-ScFv-Fc-Ly）在治疗变形链球菌感染中的应用
WO2024165057A1 (en) *	2023-02-07	2024-08-15	LaNova Medicines Limited	Antibodies and antibody-drug conjugates targeting claudin 6
WO2024209072A1 (en)	2023-04-06	2024-10-10	Genmab A/S	Multispecific binding agents against pd-l1 and cd137 for treating cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5677139A (en)	1995-04-21	1997-10-14	President And Fellows Of Harvard College	In vitro differentiation of CD34+ progenitor cells into T lymphocytes
JP2002515734A (ja)	1996-01-02	2002-05-28	カイロンコーポレイション	遺伝子改変された樹状細胞により媒介される免疫刺激
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
CN101316610A (zh) *	2005-09-22	2008-12-03	艾润·R·科恩	T细胞受体恒定区的免疫原性片段及其衍生的肽
CN101663322A (zh)	2006-12-14	2010-03-03	株式会社未来创药研究所	抗紧密连接蛋白3单克隆抗体以及使用该抗体的癌症的治疗和诊断
WO2008114733A1 (ja) *	2007-03-16	2008-09-25	Kyowa Hakko Kirin Co., Ltd.	抗Claudin-4抗体
MX2010007500A (es) *	2008-01-11	2010-10-20	Univ Tokyo	Anticuerpo anti-cldn6.
SG10201402493UA (en) *	2009-02-20	2014-10-30	Ganymed Pharmaceuticals Ag	Methods and compositions for diagnosis and treatment of cancer
ES2649389T3 (es) *	2009-11-11	2018-01-11	Ganymed Pharmaceuticals Gmbh	Anticuerpos específicos para claudina 6 (CLDN6)
EP2322555A1 (en) *	2009-11-11	2011-05-18	Ganymed Pharmaceuticals AG	Antibodies specific for claudin 6 (CLDN6)
EP2547695B1 (en) *	2010-03-16	2018-05-09	Biontech Protein Therapeutics GmbH	Tumor vaccination involving a humoral immune response against self-protein cldn18.2
US20130065310A1 (en) *	2010-04-13	2013-03-14	Sigma-Aldrich Co., Llc	Use of endogenous promoters to express heterologous proteins
EP2404936A1 (en)	2010-07-06	2012-01-11	Ganymed Pharmaceuticals AG	Cancer therapy using CLDN6 target-directed antibodies in vivo
PT2614077T (pt) *	2010-09-08	2016-11-21	Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus	Recetores de antigénio quimérico com uma região de charneira
ES2565063T3 (es) *	2011-05-13	2016-03-31	Ganymed Pharmaceuticals Ag	Anticuerpos para el tratamiento de un cáncer que expresa la claudina 6
WO2013126712A1 (en)	2012-02-22	2013-08-29	The Trustees Of The University Of Pennsylvania	Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer

2015
- 2015-03-30 HR HRP20240926TT patent/HRP20240926T1/hr unknown
- 2015-03-30 DK DK19151238.3T patent/DK3514172T3/da active
- 2015-03-30 EP EP15712657.4A patent/EP3126381B2/en active Active
- 2015-03-30 LT LTEP15712657.4T patent/LT3126381T/lt unknown
- 2015-03-30 CN CN202110278993.9A patent/CN113150109A/zh active Pending
- 2015-03-30 ES ES20160141T patent/ES2982838T3/es active Active
- 2015-03-30 DK DK20160141.6T patent/DK3708579T3/da active
- 2015-03-30 SI SI201531143T patent/SI3514172T1/sl unknown
- 2015-03-30 HU HUE15712657 patent/HUE044515T2/hu unknown
- 2015-03-30 CA CA2942459A patent/CA2942459C/en active Active
- 2015-03-30 EP EP20160141.6A patent/EP3708579B1/en active Active
- 2015-03-30 HU HUE19151238A patent/HUE050355T2/hu unknown
- 2015-03-30 DK DK15712657.4T patent/DK3126381T4/da active
- 2015-03-30 ES ES19151238T patent/ES2784537T3/es active Active
- 2015-03-30 FI FIEP20160141.6T patent/FI3708579T3/fi active
- 2015-03-30 ES ES15712657T patent/ES2717530T5/es active Active
- 2015-03-30 PL PL19151238T patent/PL3514172T3/pl unknown
- 2015-03-30 AU AU2015239683A patent/AU2015239683B2/en active Active
- 2015-03-30 US US15/124,640 patent/US10370423B2/en active Active - Reinstated
- 2015-03-30 PT PT15712657T patent/PT3126381T/pt unknown
- 2015-03-30 SI SI201532019T patent/SI3708579T1/sl unknown
- 2015-03-30 BR BR112016022727A patent/BR112016022727A8/pt active Search and Examination
- 2015-03-30 PL PL20160141.6T patent/PL3708579T3/pl unknown
- 2015-03-30 ME MEP-2019-67A patent/ME03407B/me unknown
- 2015-03-30 RS RS20190361A patent/RS58627B2/sr unknown
- 2015-03-30 PT PT201601416T patent/PT3708579T/pt unknown
- 2015-03-30 PT PT191512383T patent/PT3514172T/pt unknown
- 2015-03-30 CN CN201580017607.3A patent/CN106459165B/zh active Active
- 2015-03-30 JP JP2017503063A patent/JP6726656B2/ja active Active
- 2015-03-30 WO PCT/EP2015/056899 patent/WO2015150327A1/en active Application Filing
- 2015-03-30 HR HRP20190472TT patent/HRP20190472T4/hr unknown
- 2015-03-30 CN CN202110279207.7A patent/CN113150110A/zh active Pending
- 2015-03-30 HU HUE20160141A patent/HUE067504T2/hu unknown
- 2015-03-30 LT LTEP20160141.6T patent/LT3708579T/lt unknown
- 2015-03-30 EP EP19151238.3A patent/EP3514172B1/en active Active
- 2015-03-30 SI SI201530629T patent/SI3126381T2/sl unknown
- 2015-03-30 RS RS20240864A patent/RS65784B1/sr unknown
- 2015-03-30 PL PL15712657T patent/PL3126381T5/pl unknown
- 2015-03-30 MX MX2016012713A patent/MX2016012713A/es active IP Right Grant
2019
- 2019-04-02 CY CY20191100366T patent/CY1121539T1/el unknown
- 2019-06-18 US US16/444,510 patent/US11345731B2/en active Active
- 2019-07-31 AU AU2019210582A patent/AU2019210582B2/en active Active
2020
- 2020-02-19 JP JP2020025935A patent/JP6985440B2/ja active Active
2021
- 2021-05-31 AU AU2021203528A patent/AU2021203528B2/en active Active
- 2021-11-25 JP JP2021190855A patent/JP7451858B2/ja active Active
2022
- 2022-04-04 US US17/712,562 patent/US20220306711A1/en active Pending

Also Published As

Publication number	Publication date
PL3708579T3 (pl)	2024-08-05
ES2784537T3 (es)	2020-09-28
CA2942459C (en)	2023-03-07
CN113150109A (zh)	2021-07-23
ES2717530T3 (es)	2019-06-21
DK3708579T3 (da)	2024-07-22
AU2015239683A1 (en)	2016-09-08
DK3126381T3 (en)	2019-04-15
ES2717530T5 (es)	2022-05-06
US20170015720A1 (en)	2017-01-19
JP2022046462A (ja)	2022-03-23
AU2019210582B2 (en)	2021-03-04
EP3514172B1 (en)	2020-03-11
BR112016022727A8 (pt)	2018-12-04
DK3514172T3 (da)	2020-04-06
CN113150110A (zh)	2021-07-23
EP3514172A1 (en)	2019-07-24
JP7451858B2 (ja)	2024-03-19
CN106459165B (zh)	2021-04-20
FI3708579T3 (fi)	2024-07-16
JP6726656B2 (ja)	2020-07-22
AU2015239683B2 (en)	2019-08-22
HUE067504T2 (hu)	2024-10-28
ES2982838T3 (es)	2024-10-17
EP3126381B2 (en)	2022-02-16
HRP20240926T1 (hr)	2024-10-11
JP2020096630A (ja)	2020-06-25
HUE050355T2 (hu)	2020-12-28
PT3708579T (pt)	2024-07-17
SI3514172T1 (sl)	2020-07-31
DK3126381T4 (da)	2022-04-04
EP3126381A1 (en)	2017-02-08
RS58627B2 (sr)	2022-06-30
MX2016012713A (es)	2018-03-01
PL3126381T5 (pl)	2022-05-23
RS58627B1 (sr)	2019-05-31
WO2015150327A1 (en)	2015-10-08
CN106459165A (zh)	2017-02-22
ME03407B (me)	2020-01-20
AU2021203528B2 (en)	2022-10-13
US10370423B2 (en)	2019-08-06
JP2017518762A (ja)	2017-07-13
US20190389920A1 (en)	2019-12-26
EP3126381B1 (en)	2019-01-16
PL3126381T3 (pl)	2019-09-30
AU2021203528A1 (en)	2021-07-01
EP3708579A1 (en)	2020-09-16
HRP20190472T4 (hr)	2022-06-24
US11345731B2 (en)	2022-05-31
AU2019210582A1 (en)	2019-08-22
HUE044515T2 (hu)	2019-10-28
LT3126381T (lt)	2019-05-27
NZ723544A (en)	2021-10-29
SI3126381T2 (sl)	2022-05-31
CY1121539T1 (el)	2020-05-29
PL3514172T3 (pl)	2020-07-27
HRP20190472T1 (hr)	2019-06-14
US20220306711A1 (en)	2022-09-29
EP3708579B1 (en)	2024-05-01
SI3126381T1 (sl)	2019-07-31
JP6985440B2 (ja)	2021-12-22
CA2942459A1 (en)	2015-10-08
BR112016022727A2 (pt)	2017-10-31
LT3708579T (lt)	2024-07-25
PT3126381T (pt)	2019-04-18
SI3708579T1 (sl)	2024-09-30
RS65784B1 (sr)	2024-08-30

Publication	Publication Date	Title
IL274903A (en)	2020-07-30	cell
PT3514172T (pt)	2020-04-21	Imunorrecetores específicos de claudina-6 e epítopos de células t
IL252126A0 (en)	2017-07-31	Transduction methods and cellular processing
HK1255101A1 (zh)	2019-08-02	用於得到調節性t細胞的方法及其用途
PL3149792T3 (pl)	2019-04-30	Ogniwo litowo-siarkowe
GB201410934D0 (en)	2014-08-06	T cell
GB201420709D0 (en)	2015-01-07	Electrochemical cells and components thereof
GB201415379D0 (en)	2014-10-15	Gamma T cells and uses thereof
GB201412175D0 (en)	2014-08-20	Gamma T cells and uses thereof